Gold nanoparticles as an HIV entry inhibitor

Current HIV Research

Volumn 10, Issue 8, 2012, Pages 643-646

  Vijayakumar, S ^a   Ganesan, S ^b  

^a SRI RAMAKRISHNA INSTITUTE OF TECHNOLOGY   (India)

^b GOVERNMENT COLLEGE OF TECHNOLOGY   (India)

Author keywords

Broad spectrum; Cytotoxic; Gold nanoparticle; HIV 1; Immune system; Viral inhibition

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; GOLD NANOPARTICLE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS INHIBITION;

EID: 84872647407     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212803901383     Document Type: Article

References (27)

1. Weiss RA. How does HIV cause AIDS? Science 1993; 260: 1273-79.
2. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993; 262: 1011-8.
3. Barre-Sinoussi F. HIV as the cause of AIDS. Lancet 1996; 348: 31-5.
4. Coffin JM. Structure and classification of retroviruses. In The retroviridae. Levy, ed. New York and London, Plenum Press New York 1992: 19-49.
5. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF. Origin of HIV-1 in the chimpanzee pantroglodytes troglodytes. Nature 1999; 397: 436-41.
6. Keele BF, Van F, Heuverswyn, et al. Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1. Science 2006; 313(5786): 523-6.
7. Levy JA. Infection by human immunodeficiency virus-CD4 is not enough. N Engl J Med 1996; 335: 1528-30.
8. Dittmar MT, McKnight G, Simmons A, Clapham PR, Weiss RA, Simmonds P. HIV-1 tropsm and coreceptor use. Nature 1997; 385: 495-6.
9. Emerman M, Malim MH. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998; 280: 1880-4.
10. El-Ansary A, Al-Daihan A. On the toxicity of therapeutically used nanoparticles: An overview, J Toxico 2009; 754810: 1-9.
11. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005; 1(3): 325-7.
12. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. Angew Chem Int Ed 2010; 49: 3280-94.
13. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in the drug delivery and tissue engineering: From discovery to applications. Nano Lett 2010; 10: 3223-30.
14. Khalil H, Mahajan D, Rafailovich M, Gelfer M, Pandya K. Synthesis of zerovalent nanophase metal particles stabilized with poly (ethylene glycol). Langmuir 2004; 20: 6896-903.
15. Oliver JC, Huertas R, Lee HJ, Calon F, Pardridge WM. Synthesis of pegylated immunonanoparticles. Pharm Res 2002; 19: 1137-43.
16. Molen KH, Beller FK. Use of radioactive gold in the treatment of pleural effusions caused by metastatic cancer. J Cancer Res Clin Oncol 1979; 94: 81-5.
17. Bhattacharya J, Jastrapuria S, Sarkar T, Ghoshmoulick R, Dasgupta AK. Gold nanoparticles based tool to study protein conformational variants: implications in hemoglobinopathy. Nanomedicine 2007; 3: 14-9.
18. El-Sayed I, Huang X, El-Sayed MA. Surface Plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics, applications in oral cancer. Nano Lett 2005; 4: 829-34.
19. Mukherjee P, Bhattacharya R, Wang P, et al. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005; 11: 3530-4.
20. Lara H, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology 2010; 8: 1-10.
21. Shankar S, Bhargava Sm Sastry M. Synthesis of gold nanospheres and nanotriangles by the Turkevich approach. J Nanosci Nanotechnol 2005; 5:1721-7.
22. Zussman, Lara L, Lara HH, Bentwich Z, Borkow G. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 2003; 17: 653-61.
23. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003; 51: 229-40.
24. Chavda SC, Griffin P, Han-Liu Z, Keys B, Vekony MA, Cann AJ. Molecular determinants of the V3 loop of human immunodeficiency virus type 1 glycoprotein gp120 responsible for controlling cell tropism. J Gen Virol 1994: 3249-53.
25. Borkow G, Lapidot A. Multi-targeting the entrance door to block HIV-1. Curr Drug Targets Infect Disord 2005; 5: 3-15.
26. McDonnell GE. Chemical disinfection, antisepsis, disinfection, and sterilization. Clin Microbiol Rev 1999; 12: 111-5.
27. Lekutis C, Olshevsky U, Furman C, Thali M, Sodroski J. Contribution of disulfide bonds in the carboxyl terminus of the human immunodeficiency virus type I gp120 glycoprotein to CD4 binding. J Acquir Immune Defic Syndr 1992; 5: 78-81.